Royalty Pharma plc (Nasdaq: RPRX) today reported financial results
for the fourth quarter of 2020 and introduced full-year 2021
guidance for Adjusted Cash Receipts(1) (a non-GAAP financial
measure).
“Royalty Pharma achieved a number of major milestones in 2020,”
said Pablo Legorreta, Royalty Pharma founder and Chief Executive
Officer. "We strengthened our competitive positioning with our IPO
and inaugural debt offering; we delivered strong growth in our
business and maintained our leading share of biopharma royalty
funding in a record year. We executed on $2.4 billion of
transactions spanning five therapeutic areas, enhancing our
long-term growth while adding a diversified mix of high-quality
products. Based on our strong performance in 2020, coupled with the
growing role of royalties in the biopharma ecosystem, we are highly
confident in our long-term growth prospects.”
GAAP financial results demonstrate continued strong
operating cash flow and revenue growth
- Cash from operating activities increased 18% in the fourth
quarter; 22% for the full year (on a pro forma basis).
- Cash used in investing activities of $832 million in the
fourth quarter; $2,759 million for the full year.
- Cash (used) provided by financing activities of ($277 million)
in the fourth quarter; $1,487 million for the full year.
- Total income and other revenues of $572 million in the
fourth quarter; $2,122 million for the full year.
Non-GAAP financial results (on a pro forma basis) driven
by strong, broad-based growth across the portfolio
- Adjusted Cash Receipts(1) grew 9% to $484 million in the fourth
quarter and 1% to $1,800 million in 2020, driven primarily by the
cystic fibrosis franchise, Imbruvica and Promacta, despite royalty
expirations for mature products.
- Adjusted Cash Flow(2) grew 22% to
$423 million in the fourth quarter and 15% to $1,483 million
for the full year.
Expanded portfolio with innovative, long duration
therapies across diverse therapeutic areas
- Eight transactions announced in 2020 for 12 potentially
transformative therapies across five therapeutic areas.
- Recent royalty acquisitions for innovative therapies: Johnson
& Johnson’s seltorexant and BioCryst’s Orladeyo.
Financial guidance for 2021 (excludes contributions from
new investments)
- Royalty Pharma anticipates full-year
2021 Adjusted Cash Receipts(1) to be between $1,910 million and
$1,960 million, excluding new transactions announced subsequent to
the date of this release.
|
|
|
Financial
Summary |
Three months ended December 31 |
Twelve months ended December 31 |
|
(unaudited) |
($ and shares in millions) |
2020 |
2019Pro Forma(3) |
Change |
2020 |
2019Pro Forma(3) |
Change |
Net cash provided by operating activities (GAAP) |
566 |
478 |
18% |
2,035 |
1,673 |
22% |
Net cash used in investing activities (GAAP) |
(832) |
n/a |
n/a |
(2,759) |
n/a |
n/a |
Net cash (used in)/provided by financing activities (GAAP) |
(277) |
n/a |
n/a |
1,487 |
n/a |
n/a |
Total income and other revenues (GAAP) |
572 |
457 |
25% |
2,122 |
1,814 |
17% |
|
|
|
|
|
|
|
Adjusted Cash Receipts(1) (non-GAAP) |
484 |
446 |
9% |
1,800 |
1,776 |
1% |
Adjusted Cash Flow(2) (non-GAAP) |
423 |
347 |
22% |
1,483 |
1,290 |
15% |
|
|
|
|
|
|
|
Fully diluted shares outstanding as of December 31, 2020 |
607 |
n/a |
n/a |
607 |
n/a |
n/a |
Fourth quarter of 2020 financial results
|
Three months ended December 31 |
|
(unaudited) |
($ in millions) |
2020 |
2019Pro forma(3) |
Change |
Net cash
provided by operating activities (GAAP) |
566 |
478 |
18% |
|
|
|
|
Royalty Receipts: |
Marketer: |
Therapeutic Area: |
|
|
|
Cystic fibrosis franchise |
Vertex |
Rare disease |
159 |
116 |
37% |
Tysabri |
Biogen |
Neurology |
93 |
85 |
10% |
Imbruvica |
AbbVie,
J&J |
Cancer |
85 |
76 |
12% |
HIV franchise |
Gilead,
others |
Infectious disease |
78 |
71 |
10% |
Januvia, Janumet, Other DPP-IVs |
Merck
& Co., others |
Diabetes |
40 |
36 |
11% |
Xtandi |
Pfizer,
Astellas |
Cancer |
39 |
34 |
16% |
Promacta |
Novartis |
Hematology |
42 |
36 |
16% |
Farxiga/Onglyza |
AstraZeneca |
Diabetes |
8 |
— |
n/a |
Prevymis |
Merck
& Co. |
Infectious disease |
8 |
— |
n/a |
Crysvita |
Ultragenyx, Kyowa Kirin |
Rare disease |
3 |
— |
n/a |
Erleada |
Johnson
& Johnson |
Cancer |
3 |
1 |
140% |
Emgality |
Eli Lilly |
Neurology |
3 |
1 |
91% |
IDHIFA |
Bristol Myers Squibb |
Cancer |
3 |
— |
n/a |
Tazverik |
Epizyme |
Cancer |
0 |
— |
n/a |
Nurtec ODT |
Biohaven |
Neurology |
0 |
— |
n/a |
Trodelvy |
Gilead |
Cancer |
2 |
— |
n/a |
Evrysdi |
Roche |
Rare disease |
0 |
— |
n/a |
Lyrica |
Pfizer |
Neurology |
5 |
31 |
(83)% |
Letairis |
Gilead |
Cardiology |
9 |
22 |
(59)% |
Other Products(4) |
46 |
67 |
(31)% |
Total Royalty
Receipts |
627 |
576 |
9% |
Distributions to non-controlling interest |
(143) |
(131) |
9% |
Adjusted Cash Receipts
(non-GAAP)(1) |
484 |
446 |
9% |
Amounts shown in the table may not add due to rounding.
Net cash provided by operating activities was
$566 million in the fourth quarter of 2020, an increase of 18%
compared to the same period of 2019 on a pro forma basis, and
$2,035 million for 2020, an increase of 22% compared to 2019 on a
pro forma basis. The increase in the fourth quarter and the full
year resulted from higher cash collections from financial royalty
assets, primarily from the cystic fibrosis franchise, Tysabri, and
Imbruvica and a decline in interest paid due to a change in the
timing of interest payments on debt from quarterly to semi-annual.
This was partially offset by higher payments for operating and
professional costs in the fourth quarter of 2020 and the full
year.
Total Royalty Receipts were $627 million in the
fourth quarter of 2020, an increase of 9% compared to the same
period of 2019, and $2,344 million for 2020, an increase of 2%
compared to 2019 on a pro forma basis. Strong growth in the fourth
quarter was largely attributable to the performance of the cystic
fibrosis franchise, Imbruvica, the HIV franchise, Tysabri, Promacta
and Xtandi and the addition of new royalties, partially offset by a
decrease in royalties for Lyrica and Letairis (resulting from
losses of exclusivity). Year over year growth for the full year of
2020 was also negatively impacted by Tecfidera as the final
milestone of $150 million was received in the first quarter of
2019.
Drivers of royalty receipts in the fourth quarter of 2020 and
full year of 2020 are discussed below, based on commentary from the
marketers of the products underlying the royalties in the preceding
quarter (as royalty receipts generally lag product performance by
one calendar quarter).
- Cystic fibrosis franchise – Royalty receipts
from Vertex’s cystic fibrosis (CF) franchise, which includes
Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, all
approved for patients with certain mutations causing cystic
fibrosis, were $159 million in the fourth quarter of 2020, an
increase of 37% compared to the same period of 2019 and $551
million for 2020, up 30% compared to 2019, primarily driven by the
highly successful launch of Trikafta in the United States.
- Tysabri – Royalty receipts from Tysabri, which
is marketed by Biogen for the treatment of multiple sclerosis, were
$93 million in the fourth quarter of 2020, an increase of 10%
compared to the same period of 2019. Royalty receipts from Tysabri
were $346 million for 2020, an increase of 4% compared to 2019. The
increase was driven by demand for Tysabri in the growing
high-efficacy segment of the market.
- Imbruvica – Royalty receipts from Imbruvica,
which is marketed by AbbVie and Johnson & Johnson for the
treatment of blood cancers and chronic graft versus host disease,
were $85 million in the fourth quarter of 2020, an increase of 12%
driven by continued penetration in patients with chronic
lymphocytic leukemia. Royalty receipts from Imbruvica were $322
million in 2020, an increase of 19% compared to 2019.
- HIV franchise – Royalty receipts from the HIV
franchise, which is based on products marketed by Gilead that
contain emtricitabine, including Biktarvy, Genvoya and Truvada,
among others, were $78 million in the fourth quarter of 2020, an
increase of 10% compared to the same period of 2019. Royalty
receipts for the HIV franchise were $294 million for 2020, an
increase of 12% compared to 2019. The fourth quarter of 2020 and
full year increase was driven by strong performance of Biktarvy
offset by decreases in sales of other combination products.
- Januvia, Janumet, Other DPP-IVs – Royalty
receipts from the DPP-IVs for type 2 diabetes, which include
Januvia and Janumet, both marketed by Merck & Co., were $40
million in the fourth quarter of 2020, an increase of 11% compared
to the same period of 2019. Royalty receipts from the DPP-IVs for
2020 were relatively consistent with 2019.
- Xtandi – Royalty receipts from Xtandi, which
is marketed by Pfizer and Astellas for the treatment of prostate
cancer, were $39 million in the fourth quarter of 2020, an increase
of 16% compared to the same period of 2019, driven by demand across
various prostate cancer indications. Royalty receipts from Xtandi
were $146 million for 2020, an increase of 22% compared to
2019.
- Promacta – Royalty receipts from Promacta,
which is marketed by Novartis for the treatment of chronic immune
thrombocytopenia purpura (ITP) and aplastic anemia, were $42
million in the fourth quarter of 2020, an increase of 16% compared
to the same period of 2019. Global growth was driven by increased
use in ITP and further uptake as first-line treatment for severe
aplastic anemia in the United States. Royalty receipts from
Promacta were $144 million for 2020, an increase of 67% compared to
2019. We acquired the Promacta royalty in March 2019 and did not
record royalty receipts for Promacta until the second quarter of
2019.
Distributions to non-controlling interest,
which reduce royalty receipts to arrive at Adjusted Cash Receipts,
were $143 million in the fourth quarter, an increase of 9% compared
to the same period of 2019 on a pro forma basis. Distributions to
non-controlling interest were $544 million for 2020, an increase of
3% compared to 2019.
Adjusted Cash Receipts(1) were
$484 million in the fourth quarter of 2020, an increase of 9%
compared to the same period of 2019 on a pro forma basis,
reflecting growth in Total Royalty Receipts offset by increased
distributions to non-controlling interest. Adjusted Cash Receipts
were $1,800 million in 2020, an increase of 1% compared to 2019,
driven by an overall increase in Total Royalty Receipts stemming
from performance of the CF franchise, Imbruvica, Xtandi, the HIV
franchise and a full year of Promacta cash receipts, offset by
increased distributions to non-controlling interest.
Adjusted EBITDA(5) is
comprised of Adjusted Cash Receipts less payments for operating and
professional costs. In the fourth quarter of 2020, Adjusted EBITDA
was $434 million, a 5% increase compared to Adjusted EBITDA of
$413 million in the same period of 2019 on a pro forma basis:
- The increase was largely attributable to the 9% growth in
Adjusted Cash Receipts in the fourth quarter of 2020 as compared to
the same period in 2019.
- Payments for operating and professional costs amounted to $50
million in the fourth quarter of 2020 (representing 10% of Adjusted
Cash Receipts) as compared to $32 million (representing 7% of
Adjusted Cash Receipts) in the same period of 2019 on a pro forma
basis, with the increase primarily driven by increased payments for
fees related to the initial public offering (IPO) and other
operating costs.
Adjusted EBITDA was $1,621 million in 2020, a slight decrease of
1% compared to 2019, which was largely attributable to an increase
in payments for operating and professional costs incurred in
connection with Royalty Pharma's IPO and debt refinancing as well
as additional costs associated with operating as a public
company.
Adjusted Cash Flow(2) is
comprised of Adjusted EBITDA less ongoing development-stage funding
payments, net interest paid and miscellaneous other items. In the
fourth quarter of 2020, Adjusted Cash Flow was $423 million, a
22% increase compared to Adjusted Cash Flow of $347 million
for the same period of 2019 on a pro forma basis. The increase
primarily resulted from the growth in Adjusted Cash Receipts as
well as lower net interest paid and lower ongoing development-stage
funding payments. Items in the period included:
- Ongoing development-stage funding payments of $2 million
in the fourth quarter of 2020 were significantly lower than the
$16 million in the same period of 2019, as certain R&D
programs (primarily related to the Phase 3 adjuvant studies of
Ibrance) reached completion at the end of 2019. Ongoing
development-stage funding payments of $20 million during 2020
were significantly lower than the $83 million in 2019.
- Net interest paid of $1 million in the fourth quarter of 2020
was lower than the $50 million paid in the same period of 2019 on a
pro forma basis due to the impact of debt refinancings during 2020
and a shift to semi-annual interest payments with the issuance of
$6 billion of senior unsecured notes. Net interest paid of $95
million in 2020 was lower than the $215 million paid in 2019 on a
pro forma basis.
Adjusted Cash Flow was $1,483 million in 2020, an increase of
15%, compared to 2019 on a pro forma basis.
A more comprehensive discussion of the non-GAAP measures
utilized by Royalty Pharma to manage its business can be found in
the section of this press release entitled ‘Use of Non-GAAP
Measures.’
Key Developments Relating to the Portfolio
The key developments related to Royalty Pharma's royalty
interests are discussed below:
- Cystic fibrosis franchise: In January 2021,
Vertex Pharmaceuticals announced that the U.S. FDA accepted its
sNDA to expand the use of Trikafta to include children ages 6
through 11 years old who have at least one F508del mutation in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene or
a mutation in the CFTR gene that is responsive based on in vitro
data. The FDA granted Priority Review of the sNDA and assigned a
PDUFA target action date of June 8, 2021.
- Trodelvy: In December 2020, Gilead filed
Supplemental Biologics License Applications (sBLAs) for Trodelvy
with the FDA for full approval for the treatment of patients with
metastatic triple-negative breast cancer (mTNBC) who have received
at least two prior therapies for metastatic disease and accelerated
approval for third line metastatic urothelial cancer (mUC).
- Omecamtiv mecarbil: In November 2020, Amgen,
Cytokinetics and Servier presented the results of GALACTIC-HF
study, a Phase 3 trial of omecamtiv mecarbil in patients with heart
failure, at the American Heart Association Scientific Sessions. The
trial met the primary composite endpoint of reduction in
cardiovascular death or heart failure events, but did not meet the
secondary endpoint of reduction in cardiovascular death.
Cytokinetics subsequently regained global rights to develop and
commercialize omecamtiv mecarbil when Amgen and Servier
elected to terminate their collaboration agreement effective as of
May 2021. Following Phase 3 results and the termination of the
collaboration, Royalty Pharma recorded a $90 million write-off to
the royalty investment given the uncertainty around the future of
omecamtiv.
Summary of Recent Royalty Acquisition
Activity
- Cystic fibrosis franchise: In November 2020,
Royalty Pharma announced that it acquired the residual royalty
interest in Vertex's CF franchise owned by the CF Foundation for an
upfront payment of $575 million and a potential milestone of $75
million payable under certain circumstances. As part of previous
agreements with the CF Foundation, Royalty Pharma was obligated to
pay the CF Foundation 50% of royalties attributable to revenue over
$5.8 billion in any calendar year. This obligation was eliminated
with this transaction and Royalty Pharma is entitled to all
royalties above the previous revenue threshold.
- Orladeyo and BCX9930: In December 2020,
Royalty Pharma announced that it acquired a royalty interest in
BioCryst's Orladeyo (berotralstat), an oral therapy to prevent
attacks of hereditary angioedema (HAE) in adults and pediatric
patients 12 years and older and BCX9930, an oral Factor D inhibitor
in development for the treatment of complement-mediated diseases.
Royalty Pharma provided BioCryst an upfront cash payment of $125
million and will receive royalties of 8.75% on direct annual net
sales of Orladeyo up to $350 million, 2.75% on sales between $350
million and $550 million, no royalty on sales over $550 million,
and a tiered percentage of sublicense revenue for Orladeyo in
certain territories. In addition, Royalty Pharma will receive a
1.0% royalty on global net sales of BCX9930, if approved.
- Seltorexant: In January 2021, Royalty Pharma
announced that it acquired Minerva Neuroscience’s royalty interest
in seltorexant for an upfront payment of $60 million and up to $95
million in additional milestone payments. The additional payments
to Minerva will be contingent on the achievement of certain
clinical, regulatory and commercialization milestones. Seltorexant
is currently in Phase 3 development for the treatment of major
depressive disorder (MDD) with insomnia symptoms by Janssen
Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
Liquidity and Capital Resources
- As of December 31, 2020, Royalty Pharma had cash, cash
equivalents and marketable securities in the amount of $2.0 billion
and $5.8 billion of long-term debt with principal value of
$6.0 billion.
2021 Financial Guidance
Royalty Pharma has provided guidance for full-year 2021 as
follows:
|
Provided February 17, 2021 |
Adjusted Cash Receipts (non-GAAP) excluding new
transactionsannounced after the date of this release |
$1,910 million to $1,960 million |
|
|
Royalty Pharma expects Payments for operating and professional
costs to be approximately 9% to 10% of Adjusted Cash Receipts in
2021.
Royalty Pharma expects interest paid to be approximately $130
million for the full year of 2021. Based on the semi-annual
interest payment schedule of Royalty Pharma’s existing bonds,
interest paid is anticipated to be $64 million in each of the first
and third quarters with a de minimis amount recorded in the second
and fourth quarters. This projection assumes no additional debt
financing in 2021.
Royalty Pharma today provides this guidance based on its most
up-to-date view on its prospects. This guidance assumes no major
unforeseen adverse events and excludes the contributions from
transactions announced subsequent to the date of this press
release. Furthermore, Royalty Pharma may amend its guidance in the
event it engages in new royalty transactions which have a material
near-term financial impact on the company.
Royalty Pharma has not reconciled its non-GAAP 2021 guidance to
the most directly comparable GAAP measure, net cash provided by
operating activities, at this time due to the inherent difficulty
in accurately forecasting and quantifying certain amounts that are
necessary for such reconciliation, including, primarily, payments
for operating and professional costs, distributions from
non-consolidated affiliates and interest received. Royalty Pharma
is not able to forecast on a GAAP basis with reasonable certainty
all adjustments needed in order to project net cash provided by
operating activities at this time.
2020 to 2025 Long-Term Outlook
Royalty Pharma has updated its long-term outlook for the period
from 2020 to 2025 as follows:
|
Provided February 17, 2021 |
Previous outlook |
Adjusted Cash Receipts (non-GAAP) including new
transactions |
7% to 10% CAGR |
6% to 9% CAGR |
|
|
|
Royalty Pharma today provides this long-term outlook based on
its most up-to-date view on its prospects. This long-term outlook
assumes no major unforeseen adverse events subsequent to the date
of this press release. Furthermore, Royalty Pharma may amend its
long-term outlook in the event it engages in new royalty
transactions.
Financial Results Call
Royalty Pharma will host a conference call and simultaneous
webcast to discuss this financial results release today at 8:00
a.m., Eastern Time. A live webcast may be accessed from the
“Investors” page of the company’s website at
https://www.royaltypharma.com/investors/news-and-events/events.
Please allow at least five minutes to register and access the
presentation. A replay of the conference call and webcast will be
archived on the company's website for at least 30 days.
To ask a question during the live broadcast or listen without
internet access, please dial in at least 15 minutes in advance to
ensure a timely connection to the call. The conference call can be
accessed live over the phone by dialing (833) 519-1253, or for
international callers by dialing +1 (914) 800-3826. The passcode to
access the conference call is 7429609.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and
five development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete
or to contain all of the information you may desire. Statements
contained herein are made as of the date of this document unless
stated otherwise, and neither the delivery of this document at any
time, nor any sale of securities, shall under any circumstances
create an implication that the information contained herein is
correct as of any time after such date or that information will be
updated or revised to reflect information that subsequently becomes
available or changes occurring after the date hereof.
This document contains statements that constitute
“forward-looking statements” as that term is defined in the United
States Private Securities Litigation Reform Act of 1995, including
statements that express the company’s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of Royalty
Pharma's strategies, financing plans, growth opportunities and
market growth. In some cases, you can identify such forward-looking
statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,”
“will,” “would,” “could” or “should,” the negative of these terms
or similar expressions. Forward-looking statements are based on
management’s current beliefs and assumptions and on information
currently available to the company. However, these forward-looking
statements are not a guarantee of Royalty Pharma's performance, and
you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, and other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many
of these risks are outside of the company’s control and could cause
its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this document are
made only as of the date hereof. The company does not undertake,
and specifically declines, any obligation to update any such
statements or to publicly announce the results of any revisions to
any such statements to reflect future events or developments,
except as required by law.
Certain information contained in this document relates to or is
based on studies, publications, surveys and other data obtained
from third-party sources and the company's own internal estimates
and research. While the company believes these third-party sources
to be reliable as of the date of this document, it has not
independently verified, and makes no representation as to the
adequacy, fairness, accuracy or completeness of, any information
obtained from third-party sources. In addition, all of the market
data included in this document involves a number of assumptions and
limitations, and there can be no guarantee as to the accuracy or
reliability of such assumptions. Finally, while the company
believes its own internal research is reliable, such research has
not been verified by any independent source.
For further information, please reference Royalty Pharma's
reports and documents filed with the U.S. Securities and Exchange
Commission ("SEC") by visiting EDGAR on the SEC's website at
www.sec.gov.
Use of Non-GAAP Measures
Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow
are non-GAAP measures presented as supplemental measures to Royalty
Pharma's GAAP financial performance. These non-GAAP financial
measures exclude the impact of certain items and therefore have not
been calculated in accordance with GAAP. In each case, because
operating performance is a function of liquidity, the non-GAAP
measures used by management are presented and defined as
supplemental liquidity measures. Royalty Pharma cautions readers
that amounts presented in accordance with the definitions of
Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may
not be the same as similar measures used by other companies. Not
all companies and analysts calculate the non-GAAP measures Royalty
Pharma uses in the same manner. Royalty Pharma compensates for
these limitations by using non-GAAP financial measures as
supplements to GAAP financial measures and by presenting the
reconciliations of the non-GAAP financial measures to their most
comparable GAAP financial measures, in each case being net cash
provided by operating activities.
Royalty Pharma believes that Adjusted Cash Receipts and Adjusted
Cash Flow provide meaningful information about its operating
performance because the business is heavily reliant on its ability
to generate consistent cash flows and these measures reflect the
core cash collections and cash charges comprising its operating
results. Management strongly believes that Royalty Pharma's
significant operating cash flow is one of the attributes that
attracts potential investors to its business.
In addition, Royalty Pharma believes that Adjusted Cash Receipts
and Adjusted Cash Flow help identify underlying trends in the
business and permit investors to more fully understand how
management assesses the performance of the company, including
planning and forecasting for future periods. Adjusted Cash Receipts
and Adjusted Cash Flow are used by management as key liquidity
measures in the evaluation of the company’s ability to generate
cash from operations. Both measures are an indication of the
strength of the company and the performance of the business.
Management uses Adjusted Cash Receipts and Adjusted Cash Flow when
considering available cash, including for decision-making purposes
related to funding of acquisitions, voluntary debt repayments,
dividends and other discretionary investments. Further, these
non-GAAP financial measures help management, the audit committee
and investors evaluate the company’s ability to generate liquidity
from operating activities.
Management believes that Adjusted EBITDA is an important
non-GAAP measure in analyzing liquidity and is a key component of
certain material covenants contained within the company’s Credit
Agreement. Noncompliance with the interest coverage ratio and
leverage ratio covenants under the credit agreement could result in
lenders requiring the company to immediately repay all amounts
borrowed. If Royalty Pharma cannot satisfy these financial
covenants, it would be prohibited under the credit agreement from
engaging in certain activities, such as incurring additional
indebtedness, paying dividends, making certain payments, and
acquiring and disposing of assets. Consequently, Adjusted EBITDA is
critical to the assessment of Royalty Pharma's liquidity.
Management uses Adjusted Cash Flow to evaluate its ability to
generate cash and performance of the business and to evaluate the
company’s performance as compared to its peer group. Management
also uses Adjusted Cash Flow to compare its performance against
non-GAAP adjusted net income measures used by many companies in the
biopharmaceutical industry, even though each company may customize
its own calculation and therefore one company’s metric may not be
directly comparable to another’s. Royalty Pharma believes that
non-GAAP financial measures, including Adjusted Cash Flow, are
frequently used by securities analysts, investors and other
interested parties to evaluate companies in Royalty Pharma's
industry.
The non-GAAP financial measures used in this press release have
limitations as analytical tools, and you should not consider them
in isolation or as a substitute for the analysis of Royalty
Pharma's results as reported under GAAP. The company has provided a
reconciliation of each non-GAAP financial measure, except for its
non-GAAP outlook to the most directly comparable GAAP financial
measure, in each case being net cash provided by operating
activities at Table 5.
Royalty Pharma
plcCondensed Consolidated Income Statement
(unaudited)Table 1
|
|
|
|
|
Three months ended December 31 |
Twelve months ended December 31 |
($ in millions) |
2020 |
2019 |
2020 |
2019 |
Total income and revenues |
|
|
|
|
Income from financial royalty assets |
524 |
420 |
1,960 |
1,649 |
Revenue from intangible royalty assets |
40 |
35 |
143 |
146 |
Other royalty income |
7 |
3 |
19 |
20 |
Total income and other revenues |
572 |
457 |
2,122 |
1,814 |
|
|
|
|
|
Operating expenses |
|
|
|
|
Research and development funding expense |
8 |
16 |
26 |
83 |
Provision for changes in expected cash flows from financial royalty
assets |
129 |
(919) |
231 |
(1,019) |
Amortization of intangible royalty assets |
6 |
6 |
23 |
24 |
General and administrative expenses |
50 |
23 |
182 |
103 |
Other operating expenses |
65 |
— |
65 |
— |
Total operating expenses |
258 |
(874) |
527 |
(809) |
|
|
|
|
|
Operating income |
314 |
1,332 |
1,595 |
2,623 |
|
|
|
|
|
Other (income)/expense |
|
|
|
|
Equity in (earnings)/loss of non-consolidated affiliates |
(10) |
11 |
(44) |
33 |
Interest expense |
38 |
63 |
157 |
269 |
Other income, net |
(80) |
(189) |
(219) |
(139) |
Total other (income)/expense, net |
(53) |
(115) |
(107) |
162 |
|
|
|
|
|
Consolidated net income before tax |
367 |
1,447 |
1,702 |
2,461 |
Income tax expense |
— |
— |
— |
— |
Consolidated net income |
367 |
1,447 |
1,702 |
2,461 |
Less: Net income attributable to non-controlling interest |
(196) |
(26) |
(727) |
(113) |
Net income attributable to controlling
interest |
171 |
1,420 |
975 |
2,349 |
Amounts may not add due to rounding.
Royalty Pharma
plcSelected Balance Sheet Data
(unaudited)Table 2
($ in millions) |
As of December 31, 2020 |
As of December 31, 2019 |
Cash and cash equivalents |
1,009 |
246 |
Marketable securities |
983 |
94 |
Total financial royalty assets, net |
12,955 |
11,295 |
Total assets |
16,020 |
12,450 |
Current portion of long-term debt |
— |
282 |
Long-term debt, excluding current portion |
5,817 |
5,956 |
Total liabilities |
6,124 |
6,308 |
Total shareholders’ equity |
9,896 |
6,141 |
|
Royalty Pharma
plcCondensed Consolidated Statements of Cash Flows
(unaudited)Table 3
|
Three months ended December 31 |
Twelve months ended December 31 |
($ in millions) |
2020 |
2019 |
2020 |
2019 |
Cash flows from operating activities: |
|
|
|
|
Cash collections from financial royalty assets |
573 |
532 |
2,122 |
1,934 |
Cash collections from intangible royalty assets |
40 |
36 |
144 |
143 |
Other royalty cash collections |
6 |
3 |
18 |
27 |
Distributions from non-consolidated affiliates |
6 |
— |
42 |
14 |
Interest received |
0 |
2 |
8 |
20 |
Swap collateral received |
— |
— |
45 |
0 |
Swap collateral posted |
— |
— |
— |
(46) |
Swap termination payments |
— |
— |
(35) |
— |
Ongoing development-stage funding payments |
(2) |
(16) |
(20) |
(83) |
Upfront development-stage funding payments |
(6) |
— |
(6) |
— |
Payments for operating and professional costs |
(50) |
(18) |
(180) |
(89) |
Interest paid |
(1) |
(60) |
(103) |
(255) |
Net cash provided by operating activities |
566 |
478 |
2,035 |
1,667 |
Cash flows from investing activities: |
|
|
|
|
Distributions from non-consolidated affiliates |
— |
— |
15 |
— |
Purchases of available for sale debt securities |
— |
— |
— |
(125) |
Purchase of warrants |
— |
(9) |
— |
(9) |
Purchase of equity securities |
— |
(79) |
(50) |
(79) |
Purchase of marketable securities |
(610) |
(67) |
(1,705) |
(817) |
Proceeds from available for sale debt securities |
3 |
— |
3 |
150 |
Proceeds from sales and maturities of marketable securities |
206 |
564 |
815 |
725 |
Proceeds from equity securities |
385 |
— |
385 |
— |
Investments in non-consolidated affiliates |
(11) |
(4) |
(40) |
(27) |
Acquisitions of financial royalty assets |
(805) |
(467) |
(2,182) |
(1,721) |
Milestone payments |
— |
— |
— |
(250) |
Net cash used in investing activities |
(832) |
(63) |
(2,759) |
(2,154) |
Cash flows from financing activities: |
|
|
|
|
Distributions to shareholders/unitholders |
— |
(175) |
(285) |
(739) |
Distributions to non-controlling interest |
(143) |
(37) |
(544) |
(154) |
Distributions to non-controlling interest – other |
(107) |
— |
(181) |
— |
Dividends to shareholders |
(58) |
— |
(112) |
— |
Contributions from non-controlling interest- R&D |
2 |
— |
8 |
— |
Contributions from non-controlling interest- other |
29 |
— |
59 |
— |
Scheduled repayments of long-term debt |
— |
(74) |
(94) |
(294) |
Repayments of long-term debt |
— |
— |
(11,116) |
— |
Proceeds from issuance of long-term debt |
— |
— |
11,891 |
— |
Debt issuance costs and other |
0 |
— |
(47) |
— |
Purchase of treasury interests |
— |
— |
— |
(4) |
Proceeds from issuance of Class A ordinary shares upon IPO, net of
offering costs |
(1) |
— |
1,909 |
— |
Net cash (used in)/provided by financing
activities |
(277) |
(286) |
1,487 |
(1,192) |
Net change in cash and cash equivalents |
(544) |
130 |
762 |
(1,678) |
Cash and cash equivalents, beginning of period |
1,553 |
116 |
246 |
1,924 |
Cash and cash equivalents, end of period |
1,009 |
246 |
1,009 |
246 |
Amounts may not add due to rounding.
Royalty Pharma
plcNon-GAAP Financial Measures
(unaudited)Table 4
|
Three months ended December 31 |
Twelve months ended December 31 |
($ in millions) |
2020 |
2019Pro Forma(3) |
change |
2020 |
2019 Pro Forma(3) |
change |
Net cash provided by operating activities
(GAAP) |
566 |
478 |
18% |
2,035 |
1,673 |
22% |
|
|
|
|
|
|
|
Products: |
|
|
|
|
|
|
Cystic fibrosis franchise |
159 |
116 |
37% |
551 |
425 |
30% |
Tysabri |
93 |
85 |
10% |
346 |
333 |
4% |
Imbruvica |
85 |
76 |
12% |
322 |
271 |
19% |
HIV franchise |
78 |
71 |
10% |
294 |
263 |
12% |
Januvia, Janumet, Other DPP-IVs |
40 |
36 |
11% |
144 |
143 |
0% |
Xtandi |
39 |
34 |
16% |
146 |
120 |
22% |
Promacta |
42 |
36 |
16% |
144 |
86 |
67% |
Farxiga/Onglyza |
8 |
— |
n/a |
25 |
— |
n/a |
Prevymis |
8 |
— |
n/a |
21 |
— |
n/a |
Crysvita |
3 |
— |
n/a |
9 |
— |
n/a |
Erleada |
3 |
1 |
140% |
8 |
3 |
194% |
Emgality |
3 |
1 |
91% |
10 |
2 |
291% |
IDHIFA |
3 |
— |
n/a |
6 |
— |
n/a |
Tazverik |
0 |
— |
n/a |
1 |
— |
n/a |
Nurtec ODT |
0 |
— |
n/a |
1 |
— |
n/a |
Trodelvy |
2 |
— |
n/a |
3 |
— |
n/a |
Evrysdi |
0 |
— |
n/a |
0 |
— |
n/a |
Lyrica |
5 |
31 |
(83)% |
23 |
128 |
(82)% |
Letairis |
9 |
22 |
(59)% |
40 |
113 |
(64)% |
Other Products(4) |
46 |
67 |
(31)% |
250 |
415 |
(40)% |
Total Royalty Receipts |
627 |
576 |
9% |
2,344 |
2,302 |
2% |
Distributions to non-controlling interest |
(143) |
(131) |
9% |
(544) |
(526) |
3% |
Adjusted Cash Receipts
(non-GAAP)(1) |
484 |
446 |
9% |
1,800 |
1,776 |
1% |
Payments for operating and professional costs |
(50) |
(32) |
57% |
(180) |
(145) |
24% |
Adjusted EBITDA
(non-GAAP)(5) |
434 |
413 |
5% |
1,621 |
1,631 |
(1)% |
Ongoing development-stage funding payments |
(2) |
(16) |
(88)% |
(20) |
(83) |
(75)% |
Interest paid, net |
(1) |
(50) |
(99)% |
(95) |
(215) |
(55)% |
Swap termination payments |
— |
— |
n/a |
(35) |
(35) |
0% |
Swap collateral received |
— |
— |
n/a |
45 |
— |
n/a |
Investment in non-consolidated affiliates |
(11) |
(4) |
150% |
(40) |
(27) |
48% |
Contributions from non-controlling interest- R&D |
2 |
4 |
(36)% |
8 |
19 |
(56)% |
Adjusted Cash Flow
(non-GAAP)(2) |
423 |
347 |
22% |
1,483 |
1,290 |
15% |
Amounts
may not add due to rounding. |
|
Royalty Pharma plcGAAP
to Non-GAAP Reconciliation (unaudited)Table
5
|
Three months ended December 31 |
Twelve months ended December 31 |
($ in millions) |
2020 |
2019 Pro Forma(3) |
2020 |
2019 Pro Forma(3) |
Net cash provided by operating activities
(GAAP) |
566 |
478 |
2,035 |
1,673 |
Adjustments: |
|
|
|
|
Proceeds from available for sale debt securities(6) |
3 |
— |
3 |
150 |
Distributions from non-consolidated affiliates – investing(7) |
— |
— |
15 |
— |
Interest paid, net(7) |
1 |
50 |
95 |
215 |
Ongoing development-stage funding payments(8) |
2 |
16 |
20 |
83 |
Upfront development-stage funding payments(8) |
6 |
— |
6 |
— |
Payments for operating and professional costs |
50 |
32 |
180 |
145 |
Swap termination payments |
— |
— |
35 |
35 |
Distributions to non-controlling interest(7) |
(143) |
(131) |
(544) |
(526) |
Swap collateral received, net(7) |
— |
— |
(45) |
— |
Adjusted Cash Receipts
(non-GAAP)(1) |
484 |
446 |
1,800 |
1,776 |
Net cash provided by operating activities
(GAAP) |
566 |
478 |
2,035 |
1,673 |
Adjustments: |
|
|
|
|
Proceeds from available for sale debt securities(6) |
3 |
— |
3 |
150 |
Distributions from non-consolidated affiliates – investing(7) |
— |
— |
15 |
— |
Interest paid, net(7) |
1 |
50 |
95 |
215 |
Ongoing development-stage funding payments(8) |
2 |
16 |
20 |
83 |
Upfront development-stage funding payments(8) |
6 |
— |
6 |
— |
Swap termination payments |
— |
— |
35 |
35 |
Distributions to non-controlling interest(7) |
(143) |
(131) |
(544) |
(526) |
Swap collateral received, net(7) |
— |
— |
(45) |
— |
Adjusted EBITDA
(non-GAAP)(5) |
434 |
413 |
1,621 |
1,631 |
Net cash provided by operating activities
(GAAP) |
566 |
478 |
2,035 |
1,673 |
Adjustments: |
|
|
|
|
Proceeds from available for sale debt securities(6) |
3 |
— |
3 |
150 |
Distributions from non-consolidated affiliates – investing(7) |
— |
— |
15 |
— |
Upfront development-stage funding payments(8) |
6 |
— |
6 |
— |
Contribution from non-controlling interest- R&D(7) |
2 |
4 |
8 |
19 |
Distributions to non-controlling interest(7) |
(143) |
(131) |
(544) |
(526) |
Investment in non-consolidated affiliates(7)(9) |
(11) |
(4) |
(40) |
(27) |
Adjusted Cash Flow
(non-GAAP)(2) |
423 |
347 |
1,483 |
1,290 |
Amounts may not add due to rounding.Notes
(1) Adjusted Cash Receipts is a measure calculated with
inputs directly from the Statement of Cash Flows and includes
(1) royalty receipts: (i) cash collections from royalty
assets (financial assets and intangible assets), (ii) other royalty
cash collections, (iii) distributions from non-consolidated
affiliates, plus (2) proceeds from available for sale debt
securities (primarily Tecfidera milestone payments in 2019), and
less (3) distributions to non-controlling interest, which
represents distributions to historical non-controlling interest
attributable to a de minimis interest in RPCT held by certain
legacy investors and to a new non-controlling interest that was
created as a result of the Exchange Offer Transactions in February
2020 related to the Legacy Investors Partnerships' ownership of
approximately 18% in Old RPI. See Royalty Pharma's final prospectus
filed with the SEC on June 17, 2020 (the "Prospectus") for
additional discussion. See GAAP to Non-GAAP reconciliation at Table
5.
(2) Adjusted Cash Flow is defined as Adjusted EBITDA less
(1) ongoing development-stage funding payments, (2) interest
paid, net, (3) swap collateral (posted) or received, net, (4) swap
termination payments and (5) investment in non-consolidated
affiliates, and plus (1) contributions from non-controlling
interest – R&D, all directly reconcilable to the Statement of
Cash Flows. See GAAP to Non-GAAP reconciliation at Table 5.
(3) To aid in comparability, three and twelve months ended
December 31, 2019 figures are presented on an unaudited pro
forma basis, which adjusts certain cash flow line items as if
Royalty Pharma’s Reorganization Transactions (as described in the
Prospectus) and its initial public offering had taken place on
January 1, 2019. The most significant difference between the pro
forma and reported figures is the new non-controlling interest that
resulted from the Reorganization Transactions. A new contractual
non-controlling interest arose in the Reorganization Transactions
that results in a higher distribution to non-controlling interest
on a pro forma basis as compared to prior historical periods. Less
material differences also arise in the Royalty Receipts line for
Other Products as well as payments for operating and professional
costs and interest paid, net.
(4) Other Products include royalties on the following
products: Bosulif (a product co-developed by Royalty Pharma's joint
venture investee, Avillion, for which receipts are presented as
distributions received from nonconsolidated affiliates on the
Statement of Cash Flows), Cimzia, Conbriza/Fablyn/Viviant, Entyvio,
Lexiscan, Mircera, Myozyme, Nesina, Prezista, Priligy, Rotateq,
Soliqua and Thalomid. Other Products also include contributions
from the Legacy SLP Interest, final Tecfidera milestone payment
received in Q1 2019, a Q4 2020 payment from Biohaven in respect of
an expired option to exercise additional funding on the Biohaven
Series A Preferred Shares and a Q2 2020 distribution from Avillion
in respect of the Merck KGaA’s anti-IL-17 asset, for which
development ceased in 2020.
(5) Adjusted EBITDA is important to lenders and is defined
under the credit agreement as Adjusted Cash Receipts less payments
for operating and professional costs. Operating and professional
costs are comprised of payments for operating and professional
costs and payments for rebates from the Statement of Cash Flows.
See GAAP to Non-GAAP reconciliation at Table 5.
(6) Receipts from our Tecfidera milestone payments are
presented as Proceeds from available for sale debt securities on
the Statement of Cash Flows. In 2020, amount includes a payment
from Biohaven in respect of an expired option to exercise
additional funding of the Biohaven Series A Preferred Shares.
(7) The table below shows the line item for each adjustment
and the direct location for such line item on the Statement of Cash
Flows.
Reconciling adjustment |
Statement of Cash Flows classification |
Investments in non-consolidated affiliates |
Investing activities |
Distributions to non-controlling interest |
Financing activities |
Interest paid, net |
Operating activities (Interest paid less interest received) |
Swap collateral received, net |
Operating activities (Swap collateral received less swap collateral
posted) |
Distributions from non-consolidated affiliates - investing |
Investing activities |
Contributions from non-controlling interest- R&D |
Financing activities |
(8) Lenders consider all payments made to support R&D
activities for products undergoing late-stage development similar
to asset acquisitions as these funds are expected to generate
operational returns in the future. All ongoing and upfront
development-stage funding payments run through R&D funding
expense in net income and are added back in aggregate to net cash
provided by operating activities to arrive at Adjusted EBITDA. As a
result, Adjusted EBITDA captures the full add-back for R&D
funding payments, while Adjusted Cash Flow only reflects the
add-back for the upfront portion of development-stage funding
payments due to the fact that ongoing development-stage funding
payments are considered an ongoing business expense.
(9) Royalty Pharma considers all payments to
fund operating joint ventures that are performing research and
development activities for products undergoing late-stage
development similar to asset acquisitions as these funds are
expected to generate operational returns in the future. As a
result, amounts funded through capital calls by Royalty Pharma's
equity method investees, the Avillion entities, are deducted to
arrive at Adjusted Cash Flow, but are not deducted in Adjusted
EBITDA.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024